These notions provide strong evidence that, despite comparable biological inhibitory activity of AST1306 toward EGFR and ErbB2 tyrosine kinases in cell-free assays, the growth-inhibitory effect of AST1306 in human cancer cells and in xenograft tumor models tracks more closely with its anti-ErbB2 effects. The gene discussed is EGFR; the disease is neoplasm.